Effects of Paclitaxel,Cisplatin Combined with Recombinant Human Endostatin on the Efficacy and Related Indexes of Patients with Non-small Cell Lung Cancer
10.6039/j.issn.1001-0408.2016.30.14
- VernacularTitle:紫杉醇、顺铂联合重组人血管内皮抑制素对非小细胞肺癌患者的疗效及相关指标的影响
- Author:
Jinzhong ZHANG
;
Kun MOU
;
Jisong WANG
- Publication Type:Journal Article
- Keywords:
Recombinant human endostatin;
Paclitaxel;
Cisplatin;
Non-small cell lung cancer;
Efficacy;
Safety;
Programmed death-ligand1
- From:
China Pharmacy
2016;27(30):4218-4220
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the effects of Paclitaxel,Cisplatin combined with Recombinant human (Rh) endostatin on the efficacy and related indexes of patients with non-small cell lung cancer(NSCLC). METHODS:78 patients with Ⅲb or ⅣNSCLC were randomly divided into control group(39 cases)and observation group(39 cases). Control group received Paclitaxel injection 135-175 mg/m2,d1,intravenous infusion,once a day+Cisplatin injection 25 mg/m2,3 times a day,d1-3,intravenous infu-sion. Observation group additionally received Rh endostatin injection 15 mg/m2,adding into 500 ml 0.9% Sodium chloride injec-tion by slow intravenous infusion 3-4 h,d1-14,then stopped for 7 d. 21 d was regarded as 1 treatment course,it lasted 6 courses. Clinical efficacy,programmed death ligand-1(PD-L1)level,quality of life(QOL)score before and after treatment,and the inci-dence of adverse reactions in 2 groups were observed. RESULTS:All patients completed 2 courses of chemotherapy. There were 3 patients in observation group and 4 patients in control group quitted the study with uncompleted 6 weeks of chemotherapy due to in-tolerance or adverse reactions. The remission rate in observation group was significantly higher than control group,with statistical significance (P<0.05). Before treatment,there were no significant differences in PD-L1 level and QOL score in 2 groups (P>0.05). After treatment,PD-L1 level and QOL score in 2 groups were significantly lower than before,and observation group was lower than control group,with statistical significance (P<0.05). And there was no significant difference in the incidence of ad-verse reactions in 2 groups (P>0.05). CONCLUSIONS:Paclitaxel,Cisplatin combined with Rh endostatin can improve the short-term efficacy of patients with NSCLC,inhibit PD-L1 expression,improve QOL,and do not increase the incidence of adverse reactions.
